A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Ursula A. Matulonis et al.|Clinical Cancer Research|2019Cited by 90
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET StudyAna Oaknin, Anna V. Tinker, Rowan Miller et al.|Clinical Cancer Research|2023Cited by 80
Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized studyChristina Fotopoulou, Hani Gabra, Ignace Vergote et al.|Annals of Oncology|2013Cited by 38
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.Ursula A. Matulonis, Daniela Matei, Amit M. Oza et al.|Journal of Clinical Oncology|2016Cited by 8
Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Ursula A. Matulonis et al.|Unknown|2023Cited by 1